Vertex Pharmaceuticals Incorporated (VRTX) Stock Price Today
Key Stats
- $128.44BMarket Cap
- 1,159,876Volume
- HealthSector
- $557.9652W High
- $402.9052W Low
- 119 DaysTypical Hold Time
- $122.56BEnterprise Value
- -Div Yield
- 45% Sell | 55% BuyTrading Activity
Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $402.9 and a high of $557.96, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Most Recent News
Joby Aviation director sells shares amid eVTOL progress and financial challenges
A director at Joby Aviation sold 62,500 shares worth $380,625 while keeping a large stake. Joby is advancing its electric vertical take-off and landing (eVTOL) aircraft, aiming for passenger flights in Dubai by late 2026 pending FAA approval. Despite...
Shares of Nexalin, Integra LifeSciences, Western Digital, and Seagate plunge on operational and competition concerns.
On October 2, 2026, shares of Nexalin dropped 24.1% despite a new distribution deal, with no clear catalyst identified. Integra LifeSciences fell 21.2% after lowering its 2026 revenue outlook due to flooding disruptions. Western Digital and Seagate T...
Stablecoin Development and Armada Acquisition shares surge on key corporate moves and merger approval
On October 2, 2026, Stablecoin Development Corp. shares jumped 104.4%, trading above their 50-day moving average without a clear catalyst. Armada Acquisition Corp. II rose 68.2% following shareholder approval of its merger with Evernorth, expected to...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.